Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.  LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use pemetrexed/cisplatin as a comparator in this population.

The presentation of the LUX-Lung 3 trial will shed light on a distinct and specific NSCLC patient population, those with EGFR mutations.  EGFR mutations occur in 10 to 15 percent of NSCLC patients, and are well-established predictive biomarkers that provide specific targets for therapeutic intervention in NSCLC.  TitleLead AuthorPresentation detailsLUX-Lung 3: A randomized,
open-label, phase III study of
afatinib versus pemetrexed and
cisplatin as first-line treatment for
patients with advanced
adenocarcinoma of the lung
harboring EGFR-activating mutations.

 

James Chih-Hsin Yang, MD, PhD

 

 

 

Oral Abstract #LBA7500

Date: Monday, June 4
Time: 3:00 PM-3:15 PM CDT

 

 

 "We are excited to share the results of our pivotal LUX-Lung 3 trial, the largest and most robust ever conducted in EGFR mutation-positive patients," said Berthold Greifenberg, M.D., Vice President, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "We are continuously advancing the development of our oncology pipeline and look forward to opportunities to contribute to the bo
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
(Date:8/31/2015)... , Aug. 31, 2015  Ascendant Solutions, Inc. ... today announced that its Healthcare subsidiary, Dougherty,s Holdings, has ... on the downtown square of Springtown, Texas ... than 35 years, this community-based pharmacy has provided retail ... of Springtown . The ...
(Date:8/31/2015)... 2015  Daktari Diagnostics today announced a collaboration with Merck, ... and Canada , to develop Daktari,s ... up to $8.5 million over the next 3.5 years, will ... regulatory approval of Daktari,s HCV test. The ... can detect low levels of virus directly in a single ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3
... grounds, direct programming is superior,to cloning as a ... Nov. 20 Two major scientific,papers published this ... way to,generate patient-matched human pluripotent stem cells without ... or human or animal eggs.,Research groups in Wisconsin ...
... 20 The following statement,was released today by ... the Elizabeth Glaser Pediatric AIDS Foundation:, "Four ... Relief,(PEPFAR) began funding treatment and prevention, today,s report ... remains a devastating worldwide,pandemic, we are beginning to ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need 2
(Date:9/1/2015)... ... 2015 , ... The premier online medical education company for ... in podiatric, surgical and wound care conferences . The Residency Education Summits ... at the podium and across the table during hands-on surgical and advanced wound ...
(Date:8/31/2015)... ... 01, 2015 , ... Spinal fusion surgery – which connects ... long, arduous recovery. However, today’s minimally invasive fusions achieve similar results as traditional ... muscle damage. These advantages of minimally invasive surgery redeem the procedure’s reputation, according ...
(Date:8/31/2015)... Oaks, CA (PRWEB) , ... August 31, 2015 ... ... recently been updated to include a wealth of information for specific translation services ... has great expertise and an incredible track record of successful work. , ITC ...
(Date:8/31/2015)... ... , ... In an article based on a reader’s question that ... of treating back pain caused by a disrupted disk by using steroids rather than ... function in patients suffering from a herniated disk, the level of pain that patients ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence in ... unique to the Lake Orion area. This program is one of the most ... weight management program will incorporate group fitness and nutritional consultations to help people ...
Breaking Medicine News(10 mins):Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2
... , Text in a Document is Optimized for Reading while ... 16 Language Technologies, Inc., a software developer specializing in ... applications designed for the iPhone(TM) and iPod(R) touch at the ... Store via books.readsmart.com , are digital books ...
... Dexter-based and a Columbus, Ohio-based company are planning to expand ... Economic Development Corp. Axiobionics and Dexter Research were approved ... , , "Collaboration between state and regional economic development ... region and attracted Axiobionics from a neighboring state," said Michael ...
... in the United States , , ABBOTT ... ) today announced the initiation of SPIRIT PRIME, a clinical ... PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, ... PRIME will be used to support the regulatory filing for ...
... Prepare Medical Device Manufacturers to Comply with Expected ... Products , , HOLMDEL, N.J., June 16 ... maker of TrackWise(R) software and the market leader ... outlined its recommendations to help companies prepare for ...
... more likely to develop Alzheimer,s disease than those who aren,t ... Researchers also found, however, that the popular Alzheimer,s ... depressed individuals who suffer from mild cognitive impairment or memory ... transition period between the cognitive decline of normal aging and ...
... researchers has found "convincing evidence" that cannabis smoke damages ... of cancer development in humans. Using a newly ... University of Leicester scientists found clear indication that cannabis ... now published the findings in the journal Chemical ...
Cached Medicine News:Health News:Language Technologies Introduces ReadSmart Edition Apps(TM) for the iPhone(TM) and iPod(R) Touch; Unique Apps Improve Ergonomics of Reading while Retaining Look and Design of Print Books 2Health News:Language Technologies Introduces ReadSmart Edition Apps(TM) for the iPhone(TM) and iPod(R) Touch; Unique Apps Improve Ergonomics of Reading while Retaining Look and Design of Print Books 3Health News:Language Technologies Introduces ReadSmart Edition Apps(TM) for the iPhone(TM) and iPod(R) Touch; Unique Apps Improve Ergonomics of Reading while Retaining Look and Design of Print Books 4Health News:Two Companies Expand in Ann Arbor Area With MEDC Support 2Health News:Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials 2Health News:Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials 3Health News:Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials 4Health News:Sparta Systems(TM) Outlines Tips and Tactics to Prepare for eMDR Mandate 2Health News:Sparta Systems(TM) Outlines Tips and Tactics to Prepare for eMDR Mandate 3Health News:Depression may increase Alzheimer's risk in people with memory problems 2Health News:'Cannabis alters human DNA' -- new study 2
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Potassium in serum or plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Valproic Acid in human serum...
Medicine Products: